JUPITER NEUROSCIENCES, INC. Revenue from Contract with Customer, Including Assessed Tax
JUPITER NEUROSCIENCES, INC. (JUNS) reported Revenue from Contract with Customer, Including Assessed Tax of $24.25 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-14
- JUPITER NEUROSCIENCES, INC. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $24.25K.
- JUPITER NEUROSCIENCES, INC. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $18.65K.
- JUPITER NEUROSCIENCES, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-03-31 was $0.00.
- JUPITER NEUROSCIENCES, INC. revenue from contract with customer, including assessed tax for fiscal 2025 was $21.80K.
- JUPITER NEUROSCIENCES, INC. revenue from contract with customer, including assessed tax for fiscal 2024 was $0.00.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|
| 2026-06-30 | $24.25K 10-Q · filed 2026-08-14 | $42.90K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $18.65K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $21.80K 10-K · filed 2026-04-01 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |